Drug intelligence / Profile preview

BAY987704

Development stage: Preclinical
Lead developer: Bayer
Modality: Small Molecules
Administration: Topical

Overview

BAY987704 is an investigational sunscreening agent developed by Bayer. It was evaluated in a clinical trial (Study 18615, NCT02756988) to assess its sun protection factor (SPF) efficacy on human skin. The study involved healthy volunteers aged 18–70 and measured outcomes such as Minimal Erythema Dose (MED) and Minimal Persistent Pigment Darkening Dose (MPPD). The mechanism of action is presumed to be physical or chemical UV absorption or reflection, typical of sunscreen agents, but the specific active ingredient and molecular target are not disclosed in public sources[1][4].

Beyond the preview

Go deeper on BAY987704.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY987704.

Explore the full profile